吡咯替尼结合TAC化疗对HER2阳性乳腺癌患者疾病控制及IGF-1、EGFR蛋白表达的影响  

Effect of Pyrotinib Combined with TAC Chemotherapy on Disease Control and Expression of IGF-1 and EGFR Protein in Locally Advanced HER2 Positive Breast Cancer

作　　者：唐冬艳 黄静仪 TANG Dongyan;HUANG Jingyi(Kaiping Central Hospital,Guangdong Province,Kaiping 529300,China;不详)

机构地区：[1]广东省开平市中心医院,广东开平529300

出　　处：《中国医学创新》2022年第31期78-82,共5页Medical Innovation of China

摘　　要：目的:探究吡咯替尼结合TAC化疗对HER2阳性乳腺癌患者疾病控制及胰岛素样生长因子-1(IGF-1)、表皮生长因子受体(EGFR)蛋白表达的影响。方法:选择2019年1月-2021年11月开平市中心医院收治的100例HER2阳性乳腺癌患者,按随机数字表法将其均分为两组,各50例。化疗组采取TAC新辅助化疗方案,联合组在化疗组的基础上联合吡咯替尼。比较两组治疗效果、IGF-1、EGFR蛋白表达情况、免疫功能指标及不良反应发生情况。结果:联合组总有效率高于化疗组,差异有统计学意义(P=0.032)。治疗4个周期,联合组IGF-1、EGFR阳性表达率均低于化疗组,CD69、CD3^(+)、CD4^(+)/CD8^(+)水平均高于化疗组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:吡咯替尼+TAC化疗方案治疗HER2阳性乳腺癌,可调节IGF-1、EGFR蛋白表达,减轻免疫功能损害,安全有效。Objective:To investigate the effect of Pyrotinib combined with TAC chemotherapy on disease control and expression of insulin-like growth factor-1(IGF-1)and epidermal growth factor receptor(EGFR)protein in HER2 positive breast cancer patients.Method:A total of 100 patients with HER2 positive breast cancer admitted to Kaiping Central Hospital from January 2019 to November 2021 were selected,they were divided into two groups according to the random number table method,with 50 cases in each group.The chemotherapy group was treated with TAC neoadjuvant chemotherapy,and the combined group was treated with Pyrotinib on the basis of the chemotherapy group.The therapeutic effect,IGF-1 and EGFR protein expression,immune function indexes and adverse reactions were compared between the two groups.Result:The total effective rate in the combined group was higher than that in the chemotherapy group,the difference was statistically significant(P=0.032).After 4 cycles of treatment,the positive expression rates of IGF-1 and EGFR in the combined group were lower than those in the chemotherapy group,and the levels of CD69,CD3^(+)and CD4^(+)/CD8^(+)in the combined group were higher than those in the chemotherapy group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Pyrotinib+TAC chemotherapy regimen in the treatment of HER2 positive breast cancer can regulate the expression of IGF-1 and EGFR protein,reduce the damage of immune function,it is safe and effective.

关 键 词：吡咯替尼 TAC化疗 HER2阳性 胰岛素样生长因子-1 表皮生长因子受体 

分 类 号：R737.9[医药卫生—肿瘤]